ATE411525T1 - Nachweis einer histonmodifikation in zellfreien nukleosomen - Google Patents

Nachweis einer histonmodifikation in zellfreien nukleosomen

Info

Publication number
ATE411525T1
ATE411525T1 AT04768123T AT04768123T ATE411525T1 AT E411525 T1 ATE411525 T1 AT E411525T1 AT 04768123 T AT04768123 T AT 04768123T AT 04768123 T AT04768123 T AT 04768123T AT E411525 T1 ATE411525 T1 AT E411525T1
Authority
AT
Austria
Prior art keywords
cell
free nucleosomes
detection
nucleosomes
histone modification
Prior art date
Application number
AT04768123T
Other languages
English (en)
Inventor
Lindsay Jane Bawden
Elizabeth Ann Bone
Alan Hastings Drummond
Lindsey Ann Needham
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Application granted granted Critical
Publication of ATE411525T1 publication Critical patent/ATE411525T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Geophysics And Detection Of Objects (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04768123T 2003-08-18 2004-08-18 Nachweis einer histonmodifikation in zellfreien nukleosomen ATE411525T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0319376.0A GB0319376D0 (en) 2003-08-18 2003-08-18 Histone modification detection

Publications (1)

Publication Number Publication Date
ATE411525T1 true ATE411525T1 (de) 2008-10-15

Family

ID=28052702

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768123T ATE411525T1 (de) 2003-08-18 2004-08-18 Nachweis einer histonmodifikation in zellfreien nukleosomen

Country Status (9)

Country Link
US (3) US9128086B2 (de)
EP (1) EP1668368B1 (de)
AT (1) ATE411525T1 (de)
DE (1) DE602004017201D1 (de)
DK (1) DK1668368T3 (de)
ES (1) ES2315697T3 (de)
GB (1) GB0319376D0 (de)
SI (1) SI1668368T1 (de)
WO (1) WO2005019826A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319376D0 (en) 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
DE602006018458D1 (de) * 2005-04-29 2011-01-05 Univ California Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
US8119572B2 (en) 2005-10-24 2012-02-21 Wisconsin Alumni Research Foundation Methods for determining protein binding specificity using peptide libraries
US9035068B2 (en) 2010-09-24 2015-05-19 The Rockefeller University Phosphohistidine analogs
GB201115099D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
AU2012349855B2 (en) 2011-12-07 2017-12-07 Belgian Volition Sprl Method for detecting nucleosome adducts
GB201303575D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for detecting histone modifications in nucleosomes
GB201303576D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers
EP2775304A1 (de) * 2013-03-07 2014-09-10 Universitätsspital Basel Verfahren zum Nachweis einer entzündlichen Störung
EP3736344A1 (de) 2014-03-13 2020-11-11 Sequenom, Inc. Verfahren und prozesse zur nichtinvasiven beurteilung genetischer variationen
WO2016067029A1 (en) * 2014-10-29 2016-05-06 Singapore Volition Pte Limited Method for the enrichment of circulating tumor dna
GB201518665D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes
GB201518674D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for detecting nuleosomes containing histone modifications and variants
WO2017184873A2 (en) * 2016-04-20 2017-10-26 Aelan Cell Technologies, Inc. Compositions and methods related to the methylation of histone h1.0 protein
TWI726009B (zh) * 2016-11-28 2021-05-01 比利時商比利時意志有限公司 用親和純化法分析生物樣品中源自腫瘤之無細胞核小體、分離生物樣品中純化之腫瘤dna、檢測生物樣品中源自腫瘤之核小體表觀遺傳表位或在動物或人類受試者中檢測癌症之方法或包括組蛋白h1結合劑之套組之用途
ES2913665T3 (es) 2017-09-18 2022-06-03 Santersus Ag Método y dispositivo para la purificación de sangre a partir de ADN celular libre en circulación
WO2019084332A1 (en) 2017-10-25 2019-05-02 Aelan Cell Technologies, Inc. ANTI-H1.0K180ME2 ANTIBODIES, PREPARATION METHODS AND USES THEREOF
GB201721569D0 (en) 2017-12-21 2018-02-07 Belgian Volition Sprl Method for the detection and treatment of colorectal adenomas
US20200332370A1 (en) * 2018-01-10 2020-10-22 EpiCypher, Inc Methods for Quantification of Nucleosome Modifications and Mutations at Genomic Loci and Clinical Applications Thereof
EP3759249B1 (de) * 2018-03-01 2023-08-30 Epicypher, Inc. Quantifizierung von nukleosommodifizierungen mit chemisch definierten rekombinanten nukleosomen
CN112119166B (zh) * 2018-03-13 2025-08-22 耶路撒冷希伯来大学伊萨姆研发有限公司 无细胞dna染色质免疫沉淀的诊断应用
GB2587939B (en) 2018-04-02 2023-06-14 Grail Llc Methylation markers and targeted methylation probe panels
CA3111887A1 (en) 2018-09-27 2020-04-02 Grail, Inc. Methylation markers and targeted methylation probe panel
GB201818963D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Methof for the detection of prostate cancer
GB201818965D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Method for the detection of colorectal cancer
GB201906201D0 (en) 2019-05-02 2019-06-19 Belgian Voltion Sprl Method for the detection of protate cancer
GB201906199D0 (en) 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
AU2020336928A1 (en) 2019-08-27 2022-03-24 Belgian Volition Srl Method of isolating circulating nucleosomes
GB201912251D0 (en) 2019-08-27 2019-10-09 Belgian Volition Sprl Method of isolating circulating nucleosomes
PL4070111T3 (pl) 2019-12-02 2025-02-03 Belgian Volition Srl Zastosowanie wolnych pozakomórkowych nukleosomsów jako biomarkerów
IL296450A (en) 2020-03-20 2022-11-01 Belgian Volition Srl Triaging method using cell free nucleosome levels
JP2023544112A (ja) 2020-09-21 2023-10-20 ベルジアン ボリション エスアールエル 血液中の遊離ヌクレオソームのインラインモニタリングのための装置
CA3195344A1 (en) * 2020-11-02 2022-05-05 Matthew R. MARUNDE Improved assays to quantify chromatin targets using antibody-targeted enzyme digestion
TW202238131A (zh) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 測量無細胞核蛋白染色質片段之方法
TW202238132A (zh) 2020-12-08 2022-10-01 比利時商比利時意志有限公司 多發性硬化症之診斷方法
TW202242130A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
TW202242145A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
TW202242146A (zh) 2021-01-13 2022-11-01 比利時商比利時意志有限公司 肺癌的檢測方法
GB202108185D0 (en) 2021-06-08 2021-07-21 Belgian Volition Sprl Standardisation of nucleosome assays using biologically derived calibrants
GB202108452D0 (en) 2021-06-14 2021-07-28 Belgian Volition Sprl Triaging method using cell free nucleosome levels
WO2023073179A1 (en) 2021-10-29 2023-05-04 Belgian Volition Srl Homogeneous immunoassay method
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
US12053567B2 (en) 2021-12-27 2024-08-06 Santersus Ag Method and device for removal of circulating cell free DNA
US20250197944A1 (en) 2022-03-11 2025-06-19 Belgian Volition Srl Differential diagnosis method
GB202205212D0 (en) 2022-04-08 2022-05-25 Belgian Volition Sprl Method for transplant organ health assessment
US20260072040A1 (en) 2022-08-25 2026-03-12 Belgian Volition Srl Method for measuring cell free chromatin
EP4577835A1 (de) 2022-08-25 2025-07-02 Belgian Volition SRL Verfahren zum nachweis von demenz
WO2024133222A1 (en) 2022-12-19 2024-06-27 Belgian Volition Srl Assessment of biological samples for nucleic acid analysis
WO2024133225A1 (en) 2022-12-19 2024-06-27 Belgian Volition Srl Calibration
GB202300607D0 (en) 2023-01-16 2023-03-01 Belgian Volition Srl Proteins and methods for isolating circulating nucleosomes
GB202303562D0 (en) 2023-03-10 2023-04-26 Belgian Volition Sprl Sample collection for liquid biopsy
EP4695610A1 (de) 2023-04-14 2026-02-18 Belgian Volition SRL Diagnoseverfahren unter verwendung zellfreier nukleosomspiegel
WO2024223947A1 (en) 2023-04-28 2024-10-31 Belgian Volition Srl Use of cell free nucleosomes as biomarkers of carcinomas
GB202307768D0 (en) 2023-05-24 2023-07-05 Belgian Volition Srl Use of cell free nucleosomes as biomarkers
GB202310137D0 (en) 2023-07-03 2023-08-16 Belgian Volition Srl Method for the detection of cancer
WO2025012440A1 (en) 2023-07-13 2025-01-16 Belgian Volition Srl Method for detection of the potential of a body fluid sample to produce extracellular traps
WO2025061853A1 (en) 2023-09-19 2025-03-27 Belgian Volition Srl Lateral flow test device
WO2025093747A1 (en) 2023-11-02 2025-05-08 Belgian Volition Srl Novel rapid high-throughput method of netosis induction and inhibition with physiologically relevant molecules
WO2025181348A1 (en) 2024-03-01 2025-09-04 Belgian Volition Srl Method for determining the origin of circulating dna
WO2025253002A1 (en) 2024-06-07 2025-12-11 Belgian Volition Srl Sample collection for liquid biopsy
WO2026052765A1 (en) 2024-09-05 2026-03-12 Belgian Volition Srl Method using nucleosome levels

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2934299A (en) * 1998-03-18 1999-10-11 Roche Diagnostics Gmbh Detection of apoptotic products
US20040197838A1 (en) * 2001-08-03 2004-10-07 Allis C David Phosphorylated histone h2b as apoptosis marker
IL161856A0 (en) * 2001-11-30 2005-11-20 Pfizer Prod Inc Methods for detecting cells with numerical chromosomal abnormalities
JP2005517431A (ja) 2002-02-20 2005-06-16 ユニバーシティ オブ バージニア パテント ファウンデーション ヒストン修飾マーカーを利用した非侵襲的診断検査
US20060073517A1 (en) * 2003-03-10 2006-04-06 Allis C D Post-translational modifications of proteins as regulatory switches
GB0319376D0 (en) 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
DE602006018458D1 (de) * 2005-04-29 2011-01-05 Univ California Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose

Also Published As

Publication number Publication date
DK1668368T3 (da) 2009-02-23
EP1668368A1 (de) 2006-06-14
US20070160989A1 (en) 2007-07-12
US10408831B2 (en) 2019-09-10
ES2315697T3 (es) 2009-04-01
GB0319376D0 (en) 2003-09-17
US20150330996A1 (en) 2015-11-19
US20190353653A1 (en) 2019-11-21
DE602004017201D1 (de) 2008-11-27
WO2005019826A1 (en) 2005-03-03
SI1668368T1 (sl) 2009-04-30
EP1668368B1 (de) 2008-10-15
US9128086B2 (en) 2015-09-08

Similar Documents

Publication Publication Date Title
ATE411525T1 (de) Nachweis einer histonmodifikation in zellfreien nukleosomen
EP2275815A3 (de) Verbesserte Immunoassayverfahren
DE60228557D1 (de) Candida-nachweis
BRPI0618713B8 (pt) cardiolipina modificada e seus usos
ATE393914T1 (de) Nachweis von biomolekülen unter verwendung poröser biosensoren und raman-spektroskopie
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
WO2002001230A3 (en) Rapid and sensitive detection of protein aggregation
BRPI0610092B8 (pt) métodos para a detecção de um analito e de um ácido nucleico em uma amostra, e de sintetização de uma molécula de ácido nucleico ou de análogo de ácido nucleico, kit reagente, uso do mesmo, molécula de ácido nucleico ou de análogo de ácido nucleico e produto associado
GB2404022B (en) Competitive assays for the detection of methamphetamine group drugs
WO2004057341A3 (en) Cvd assay
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
WO2008054724A3 (en) Monoclonal antibodies against osteopontin
BRPI0416270A (pt) método para detectar um analito em uma amostra, e, método e kit para detectar um anticorpo especìfico de uma amostra
EP1560025A3 (de) Marker spezifisch für Diabetes
ATE503187T1 (de) Nachweis eines therapeutischen antikörpers in einem versuchstier
WO2005102938A3 (en) Antibodies specific for bcr-abl fusion protein and uses thereof
DE60140346D1 (de) System zur internen, qualitativen und quantitativen überprüfung von zellmarker-indices
CY1113013T1 (el) Βελτιωμενες μεθοδοι ανοσολογικων δοκιμασιων
EP2444812A3 (de) Verbesserte Immunoassayverfahren
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
WO2005037056A3 (en) Method for the detection of a biomolecule in a test sample
EP2407787A3 (de) Verfahren für den Nachweis von L523S-Expression in biologischen Proben
WO2006124888A3 (en) Detection of antigen specific immunocomplexes
CY1117148T1 (el) Βελτιωμενες μεθοδοι ανοσοπροσδιορισμου

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1668368

Country of ref document: EP